A Case Controlled Etiologic Study of Sarcoidosis (ACCESS) - Catalog

  • Name

    A Case Controlled Etiologic Study of Sarcoidosis (ACCESS)

  • Accession Number

    HLB00300404a

  • Acronym

    ACCESS

  • Related studies
  • BSI Study IDs

    ACC

  • Is public use dataset

    False

  • Keywords
  • Ingestion Status
    Released
  • Has Study Datasets

    True

  • Has Specimens

    True

  • Specimen ID Type
    Coded
  • Study Website
  • The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

    False

  • Clinical Trial URLs
  • Study type
    Epidemiology Study
  • Collection Type
    Open BioLINCC Study
  • Cohort type
    Adult
  • Interventions
  • Study Open Date (Data)

    2009-10-01

  • Study Open Date (Specimens)

    2009-10-01

  • Date materials available

    2008-10-01

  • Last updated

    2005-12-21

  • Study period

    June 1995 - March 2003

  • Study Contacts
  • NHLBI Division

    DLD

  • Classification
    Lung
  • HIV study classification
    non-HIV
  • COVID study classification
    non-COVID
  • Pre-Website # of Specimens Shipped

    11211

  • # of Returned Specimens

    0

  • Primary Publication URLs
    N/A
  • Conditions
    Lung Diseases
    Sarcoidosis
  • Objectives

    To determine the etiology of sarcoidosis by establishing a case control, multi-center study. In addition to etiology, this study also sought to examine socioeconomic variables and the clinical course of patients with sarcoidosis, including quality of life.

  • Background

    Sarcoidosis is a chronic granulomatous disorder of unknown cause that is characterized by activation of T-lymphocytes and macrophages. For many years sarcoidosis was presumed to be an atypical manifestation of tuberculosis because of the similarity between the inflammatory responses of the two diseases. However, as culture techniques became more widely employed to diagnose tuberculosis and it became less common, it became clear that sarcoidosis was not simply a variation of tuberculosis. Data on the etiology of sarcoidosis have come from diverse sources: in clinical investigations, alveolitis has been found to precede granulomatous inflammation; in case control studies, familial aggregation has been identified; and in case reports, recurrence of granulomatous inflammation has been observed after lung transplantation. The cause may not prove to be a single, known exposure. Interactions of exposures with genetic dispositions could have important implications for our understanding of immune responses as well as the pathogenesis of sarcoidosis.

  • Participants

    736 patients with sarcoidosis enrolled within 6 months of diagnosis from 10 clinical centers in the U.S. Using the ACCESS sarcoidosis assessment system, organ involvement was determined for the whole group and for subgroups differentiated by sex, race, and age (<40 or 40 and older). Cases were matched with a control, and there was a two-year follow-up on cases. The ACCESS group proposed an instrument fo defining organ involvement in sarcoidosis. Biological specimens included DNA, plasma, and bronchoalveolar lavage samples were obtained. The data set includes 718 cases, 686 controls, and two-year follow-up data on 241 cases.

  • Design
  • Conclusions

    The initial presentation of sarcoidosis is related to sex, race and age, and it tends to remain stable over two years in the majority of patients. The etiology is probably multifactoral with both genetic and environmental factors contributing.

  • Disease classification
  • Publications
  • Mat types
    Bronchial Lavage
    DNA
    Peripheral Blood Mononuclear Cells
    Plasma
  • Network

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    Cases: 718

    Controls: 686


    Last Modified: July 1, 2024, 2:30 p.m.
  • Age

     

    Case

    Control

    Total Subjects

    18-29

    80

    75

    155

    30-39

    247

    222

    469

    40-49

    214

    224

    438

    50-59

    129

    118

    247

    >=60

    48

    47

    95


    Last Modified: July 1, 2024, 2:30 p.m.
  • Sex

     

    Case

    Control

    Total Subjects

    Male

    261

    243

    504

    Female

    457

    443

    900


    Last Modified: July 1, 2024, 2:30 p.m.
  • Race

     

    Case

    Control

    Total Subjects

    White

    393

    380

    773

    Black or African American

    325

    306

    631


    Last Modified: July 1, 2024, 2:30 p.m.

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. PDF Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types

    Last Modified: Nov. 30, 2015, 10:16 a.m.
  • General Freeze/Thaw Status
  • Visits (Vials)

    10/31/2024

    Plasma

    DNA

    PBMC

    Bronchoalveolar Lavage (BAL)

    Total Vials

    14,488

    29,389

    1,394

    633

    45,904


    Last Modified: Oct. 31, 2024, 9:24 a.m.
  • Visits (Subjects)

    10/31/2024

    Plasma

    Total number of subjects

    Average volume (mL) per subject

    1,424

    11.87

     

    DNA

    Total number of subjects

    Average mass (mg) per subject

    1,426

    20.61

     

    PBMC

    Total number of subjects

    Average volume (mL) per subject

    1,218

    1.14

     

    Bronchoalveolar Lavage (BAL)

    Total number of subjects

    Average volume (mL) per subject

    73

    8.67


    Last Modified: Oct. 31, 2024, 9:24 a.m.